Thyroid cancer is the most common endocrine malignancy. Although medullary thyroid 81 cancer (MTC), arising from the calcitonin secreting para-follicular cells, only accounts for ~5% of 82 thyroid cancers (1), nearly 50% of patients present with stage III or IV disease and only 21% of 83 patients presenting with stage IV disease survive 10 years (2) . 84
In ~25% of MTC there is a germline RET mutation (3) predisposing to multiple endocrine 85 neoplasia type 2 (MEN2), a dominantly inherited endocrine tumour predisposition syndrome 86 characterised by predisposition to the development of young onset MTC and often primary C cell 87 hyperplasia (CCH), a precursor to MTC (4). Other features may also occur such as 88 phaeochromocytoma, primary hyperparathyroidism (HPT) and, rarely, developmental abnormalities, 89 for example, a marfanoid habitus and ganglioneuromatosis of the mouth and gut (4). 90
The majority of RET mutations predisposing to MEN2 result in single amino acid 91 substitutions affecting key residues in the extra-cellular and kinase domains of the RET receptor (5,6) 92 causing inappropriate constitutive RET activation. Detection of a germline RET mutation, enables 93 pre-symptomatic interventions such as prophylactic thyroidectomy to be offered to at-risk gene 94 carriers (6). Thus all individuals presenting with MTC or primary CCH should be offered germline 95
RET testing (7); however, some families with an apparent predisposition to MTC/CCH do not harbour 96 a germline RET gene alteration (8, 9) suggesting that further predisposing gene alterations remain to be 97 identified. We investigated a kindred with non-RET MTC/CCH and detected a novel constitutional 98 frameshift mutation in ESR2 encoding the beta subunit of the oestrogen receptor, ERβ (10). 99
Results 101 102
Case Report 103
The index case presented age 22 years with MTC ( Supplementary Material, Fig. S1 ). 104
Although no constitutional mutation of exons 10, 11, or 13-16 of RET was detected, in view of the 105 young age of diagnosis his monozygotic twin brother was offered follow-up and underwent 106 thyroidectomy age 33 years because of abnormal pentagastrin stimulation testing; histological review 107 showed the presence of CCH. Prophylactic thyroid surgery was then undertaken in the offspring of 108 both brothers (individuals III:1-5); individuals III:2 and III:3 were found to have CCH and individuals 109 III:1, III:4 and III:5 to have normal thyroid tissue. Pentagastrin stimulation testing was subsequently 110 offered to the wider family and individual I:1 noted to have mildly abnormal results. In the index case, 111 further constitutional molecular genetic testing did not detect any mutations in the remaining exons of 112 RET, karyotype analysis was normal and array CGH analysis did not demonstrate any clinically 113 significant CNVs (data not shown). We therefore hypothesised a novel gene alteration was 114 predisposing to MTC/CCH in the family and undertook exome sequencing in two affected members 115 (II:3 and III:3). 116 117
Identification of Germline ESR2 mutation in Familial MTC/CCH 118
We filtered the variants identified using the dbSNP (11), NHLBI Exome Variant Server 119 (EVS) (12) and 1000 genomes (13) datasets looking for potentially disrupting variants present in both 120 samples, prioritising frameshift and nonsense changes. We did not identify any deleterious alterations 121 in the genes known to be mutated in hereditary cancer predisposition (14, Supplementary Material, 122 Table S1) but did identify a novel frameshift alteration of ESR2 (c.948delT; p.Gly318Alafs*22) 123 present in both affected individuals but not in the NHLBI EVS nor in 2577 individuals from the 1000 124 genome project (12, 13) . 125
Constitutional ESR2 sequencing in other family members demonstrated the c.948delT variant 126 to be present in the two family members found to have CCH (individuals II:1 and III:2) but not in the Page 6 of 27 three (individuals III:1, III:4, III:5) with normal thyroid histology ( Fig. 1A , Supplementary Material, 128 LOH studies using closely linked microsatellite markers in archived tumour material, we did not 136 detect a somatic alteration of ESR2 (data not shown). Whole genome copy number analysis by 137 molecular inversion probe technology did not reveal any pathological CNVs affecting either 138 chromosomes 14 or 10 (harbouring the ESR2 and RET loci respectively) (Supplementary Material, 139 To ascertain whether constitutional alterations of ESR2 might be involved in other cases of 143 apparent MTC predisposition, we undertook sequencing of the coding region of ESR2 in 19 144 individuals with apparently isolated MTC, eight of whom were diagnosed <40 years of age (mean age 145 at diagnosis 47.5y, range 33-71y, SEM 2.96). The entire coding region of RET had been previously 146 sequenced and no alterations detected other than known polymorphisms. We identified a novel 147 germline missense alteration, c.382G>C; p.V128L, in a female who developed an apparently isolated 148 MTC age 36 years ( Fig. 2A ). This variant was also detected in a pair of siblings, one of whom had a 149 papillary thyroid cancer age 60 years and the other a medullary thyroid cancer age 57 years. We did 150 not detect any constitutional ESR2 alterations, other than known polymorphisms, in a further three 151 families with familial non-RET MTC (data not shown). CNVs of chromosomes 14 or 10 were detected. Although this variant was not present in the NHLBI 156 EVS (12) or 1000 genome project (13) datasets, further analysis using SIFT (15) predicted it to be 157 tolerated, and PolyPhen-2 (16) to be benign; we were therefore unable to exclude that ESR2 158 c.382G>C may represent a rare polymorphism and did not evaluate further. 159
160
No somatic mutations of ESR2 detected in sporadic MTC 161
As hereditary cancer predisposing genes are often implicated in sporadic tumours (17), we 162 investigated whether somatic mutations of ESR2 also occurred in sporadic MTC. However, direct 163 sequencing of ESR2 in 15 fresh frozen sporadic MTC did not reveal any alterations other than known 164 polymorphisms (data not shown). Whilst the cosmic (18) and TCGA data sets (19), containing data 165 for over 21,000 tumours, did not have any data regarding ESR2 in MTC, we did note the presence of 166 somatic ESR2 mutations in other tumours of neuroectodermal origin, for example glioma and 167 melanoma. 168
ESR2 c.948delT is associated with unrestrained ERα driven cell proliferation 170
We then sought to understand how this rare novel ESR2 frameshift alteration might cause 171 tumourigenesis. Initially we determined stability of the ESR2 c.948delT mutant compared to wild-172 type (wt) ESR2. Transient transfection of HCT116 cells, followed by the addition of the transcription 173 inhibitor, actinomycin, resulted in significantly lower ESR2 c.948delT mRNA levels over a 24 hour 174 time period compared with wtESR2 indicating reduced stability of the mutant mRNA (Supplementary 175
Material, Fig. S3 ). 176 ESR2-encoded ERβ forms either homo-or, preferentially, hetero-dimers with ESR1-encoded 177
ERα to bind DNA at specific estrogen-responsive elements (EREs) within the promoters of target 178 genes to regulate transcription (20) . ERα is the more potent activator and ERβ can repress ERα; thus 179 transcriptional activity is determined by the relative ERα/ERβ proportion (21) (22) (23) . In both HCT116 and MCF-7 cells, in response to either E2 or PPT agonist, wtESR1 activated 188 the ERE, as indicated by increased luciferase expression, and this was significantly restrained in the 189 presence of wtESR2. However, co-transfection of wtESR1 with ESR2 c.948delT restored expression 190 to a level similar to that seen with wtESR1 alone indicating that the ESR2 c.948delT mutant has lost 191 the ability to restrain ERα-mediated activation of the ERE (Fig. 4) . 192
We then investigated how inappropriate activation of the ERE by c.948delT might cause 193 MTC tumourigenesis. Inappropriate up-regulation of RET activity causing MTC is well established 194
(4) and we noted that the RET promoter (-34 to -314) contains three ERE (24). Furthermore, in in 195 vitro studies, RET has been established as an ER target gene (25) (26) (27) . We therefore investigated 196 whether loss of ERβ function might lead to up-regulation of RET expression. 197 As MCF7 cells have intrinsic ER activity, we used HCT116 cells to investigate the effect of 198 ESR2 c.948delT on RET expression. Co-transfection of wtESR1 with wtESR2 in HCT116 cells, in the 199 presence of either E2 or PPT, resulted in decreased RET expression as compared with wtESR1 alone; 200 however, over-expression of wtESR1 and ESR2 c.948delT, restored RET expression to a level similar 201 to that seen with wtESR1 alone (Fig. 5A, B) . 202
In vivo, RET immunostaining using archived sections from the ESR2 c.948delT associated 203 MTC (individual II:3) and analysis of archived stained slides showing CCH (individual II:1) 204 demonstrated increased RET staining (Fig. 5C ). In particular, the intensity of RET expression in the 205 MTC was stronger than in corresponding normal thyroid tissue and similar to that in an MEN2-206 associated MTC with a known constitutional RET mutation (Fig. 5C ). Analysis of RET exons 10, 11 207 and 13-16 in the ESR2 c.948delT associated MTC did not detect a somatic mutation to account for the 208 increased expression (data not shown). 209 210 Page 9 of 27
Discussion 211
By targeted capture array-based exome sequencing we detected a novel loss of function ESR2 212 mutation in a family with predisposition to MTC/CCH. As the interpretation of novel rare variants 213 identified through next generation sequencing approaches in isolated families is challenging, we 214 sought functional evidence to establish pathogenicity. 215
Initially we demonstrated tumour specific loss of ERβ expression in the c.948delT associated 216 MTC which we considered indicative of loss of function as ERβ is known to be expressed by human 217 para-follicular C cells (28). Whilst ESR2 knockout mice display a phenotype more in keeping with a 218 reduced fertility phenotype in females rather than one associated with tumourigenesis (29), ESR2 has 219 been shown to inhibit cell proliferation in vitro (30) and tumour formation in nude mice (31). 220
Although we did not identify a somatic ESR2 alteration in this tumour and were unable to investigate 221 ESR2 promoter hypermethylation, we note that ESR2 promoter hypermethylation associated with 222
ERβ down-regulation has been detected in a variety of tumour types (32) (33) (34) . As with other cancer 223 predisposition syndromes (35), it is also probable that additional somatic mutations are required in the 224 transition from normal thyroid to MTC and we did detect low level loss of chromosomes 3 and 13. 225
It is likely that ERβ loss of function in MTC is rare as we did not detect loss of ERβ 226 expression in 12 apparently sporadic MTC tumours nor an intragenic ESR2 mutation in 15 sporadic 227
MTCs. Interestingly, studies of MTC have indicated that RAS and RET are the dominant driver 228 pathways in tumourigenesis, with few mutations being detected in other genes and none in ESR2 (36). 229
Our findings are also in keeping with large scale studies of sporadic tumours where no CNVs, and 230 only one putative mutation of ESR2 (missense alteration in a single papillary thyroid cancer), have 231 been detected in thyroid tumours (18, 19) . Such relative infrequency of somatic mutation in sporadic 232 tumours in genes predisposing to hereditary cancers is well recognised, for example the low rate of 233 somatic BRCA1 and BRCA2 mutations in sporadic breast cancer (37,38). We did note that somatic 234 ESR2 mutations have been detected in other neuroectodermal derived tumours such as glioma and 235 melanoma and also breast cancer samples indicating that inappropriate up-regulated ERα activity may 236 also be involved in their tumourigenesis (18, 19) .
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We did not detect a constitutional ESR2 mutation in a further three families with an apparent 238 genetic predisposition to MTC and CCH and it is likely that, akin to other familial cancer 239 predisposition syndromes (39), there is also heterogeneity in the genetic predisposition to MTC/CCH. 240
The association of increased RET activity with MTC tumourigenesis is well established (4) 241 and here we demonstrate a novel mechanism of MTC tumourigenesis whereby loss of ERβ function 242 results in ERα-driven RET expression, likely mediated through the ERE on the RET promoter. Whilst 243 there may be an unidentified constitutional RET mutation, or another mechanism of RET up-244 regulation, we have also shown ESR2 c.948delT to cause increased cellular proliferation indicating a 245 likely role in tumourigenesis; however, we cannot exclude that other mechanisms of ERβ action may 246 also be involved, for example through loss of ERβ mediated inhibition of HIF-1α causing 247 inappropriate HIF pathway activation (40). 248
Although we detected a mutation in just one family, our results suggest that constitutional 249 ESR2 mutation is of high penetrance for CCH/MTC. However, as individual I:1 has not overtly 250 presented with MTC, we cannot exclude that there may be variable penetrance, as occurs for germline 251 RET mutations and in other familial cancer predisposition syndromes such as paraganglioma-252 phaeochromocytoma predisposition (4, 41). 253
It is interesting to speculate whether constitutional ESR2 mutations are also associated with 254 predisposition to HPT and phaeochromocytoma. These tumours have not occurred to date in the 255 family (relevant clinical and laboratory investigation has been undertaken) and whole exome 256 sequencing of both constitutional DNA from individuals with apparent genetic predisposition to 257 phaeochromocytoma (12 individuals) and sporadic phaeochromocytoma (seven tumours) has not 258 detected any deleterious ESR2 mutations (ERM unpublished observations). Nonetheless, given the 259 known tumour predisposition associated with dysregulated RET activity, it would seem prudent to 260 offer clinical surveillance for phaeochromocytoma and HPT, and prophylactic thyroidectomy, where a 261 loss of function constitutional ESR2 mutation is detected. 262
The investigation of rare familial cancer predisposition often provides important insights into 263 cell biology with the potential for novel therapeutic approaches (42) and our findings also provide 264 further evidence of the interaction between ERα and RET in tumourigenesis. Many invasive breast cancers expressing ERα also express RET (4) and in recent pre-clinical models of breast cancer, 266 targeting both RET and ERα decreases the growth and metastatic potential of breast cancer cells (43) . 267
Thus tumours associated with loss of ERβ function might be suitable candidates for therapeutic agents 268 targeting the RET pathway (44), RET tyrosine kinase active site (45) or ERα (46) . 269
In summary, our data is the first to identify a novel genetic cause for familial MTC since the 270 identification of the RET gene. We demonstrate a novel mechanism promoting up-regulation of RET 271 activity through constitutional ESR2 mutation which provides opportunities for pre-symptomatic 272 testing and potential novel therapeutic strategies. Heat-induced antigen retrieval was performed using EDTA buffer as previously described (48). 289
Immunostaining was performed using the Ventana Benchmark Automated Slide Stainer (Ventana 290
Medical Systems) with antibodies against ERβ (Leica Biosystems, 1:50), calcitonin (Dako IR515) and 291 RET (Abcam EPR2871, 1:500). 292 293
Loss of Heterozygosity (LOH) analyses 294
Microsatellite markers were used to determine LOH at the ESR2 locus on chromosome 295 14q23.2: one, previously described (49) The OncoScan ® FFPE assay kit platform was utilized to identify whole-genome copy number 303 variations (CNV) as previously described (50). 
Western Blotting 331
Western blots, performed as described previously (51), were probed with antibodies against 332 RET (C31B4, Cell Signaling Technology), 1:1000; ERβ (H150, Santa Cruz Biotechnology), 1:1000; 333 c-Myc, 1:1000 and β actin; 1:10,000 (Sigma-Aldrich). Antigen-antibody complexes were detected 334 using ECL Plus (Amersham Biosciences). 335 336
Luciferase Reporter Assays 337
Luciferase reporter assays were performed using the Cignal ERE Reporter Kit (Qiagen). 338 HCT116 (7,500 cells/ well) and MCF-7 (15,000 cells/ well) cells were reverse transfected with 50ng 339
Cignal ERE reporter along with 100ng ER expression vectors with TransIT LT1. After 24h hormone 340 incubation, cells were harvested with lysis buffer (Promega) and the firefly and renilla luciferase 341 activities determined with a dual luciferase assay kit (Promega), measuring luminescence with a 342
Centro LB960 microplate luminometer (Berthold Technologies). 343 344
Cell Proliferation 345
Proliferation of MCF-7 cells was determined using the Celltiter-Glo® Luminescent Cell 346
Viability Assay (Promega). In brief, 12,500 MCF-7 cells were reverse transfected with ER expression 347 vectors and TransIT LT1 in 96 wells and then treated with hormones as indicated for 72h prior to 348 analysis of the luminescent signal using the Centro LB960 microplate luminometer (Berthold 349 Technologies). AIP   DDB2  FANCL  PALB2  SLX4  ALK  DICER1  FANCM  PHOX2B  SMAD4  APC  DIS3L2  FH  PMS1  SMARCB1  ATM  EGFR  FLCN  PMS2  STK11  BAP1  EPCAM  GATA2  PRF1  SUFU  BLM  ERCC2  GPC3  PRKAR1A  TMEM127  BMPR1A  ERCC3  HNF1A  PTCH1  TP53  BRCA1  ERCC4  HRAS  PTEN  TSC1  BRCA2  ERCC5  KIT  RAD51C  TSC2  BRIP1  EXT1  MAX  RAD51D  VHL  BUB1B  EXT2  MEN1  RB1  WRN  CDC73  EZH2  MET  RECQL4  WT1  CDH1  FANCA  MLH1  RET  XPA  CDK4  FANCB  MSH2  RHBDF2  XPC  CDKN1C  FANCC  MSH6  RUNX1  CDKN2A  FANCD2  MUTYH  SBDS  CEBPA  FANCE  NBN  SDHAF2  CEP57  FANCF  NF1  SDHB  CHEK2  FANCG  NF2  SDHC  CYLD  FANCI  NSD1  SDHD   Table S1 . List of genes on TruSight Cancer Panel.
(http://www.illumina.com/products/trusight_cancer.html)
